Suppression of MEK/ERK Signaling Pathway Enhances Cisplatin-induced NF-κB Activation by Protein Phosphatase 4-mediated NF-κB p65 Thr Dephosphorylation
Open Access
- 1 June 2004
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (25), 26143-26148
- https://doi.org/10.1074/jbc.m402362200
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κBJournal of Clinical Investigation, 2001
- Control of apoptosis by Rel/NF-κB transcription factorsOncogene, 1999
- Aberrant rel/nfkb genes and activity in human cancerOncogene, 1999
- IκB Kinases Phosphorylate NF-κB p65 Subunit on Serine 536 in the Transactivation DomainJournal of Biological Chemistry, 1999
- NF- κ B and chemoresistance: potentiation of cancer drugs via inhibition of NF- κ BDrug Resistance Updates, 1999
- Activation of Nuclear Factor-κB-dependent Transcription by Tumor Necrosis Factor-α Is Mediated through Phosphorylation of RelA/p65 on Serine 529Journal of Biological Chemistry, 1998
- Phosphorylation of NF-κB p65 by PKA Stimulates Transcriptional Activity by Promoting a Novel Bivalent Interaction with the Coactivator CBP/p300Molecular Cell, 1998
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- The Transcriptional Activity of NF-κB Is Regulated by the IκB-Associated PKAc Subunit through a Cyclic AMP–Independent MechanismCell, 1997
- Transactivation Domain 2 (TA2) of p65 NF-κBJournal of Biological Chemistry, 1995